NCT00994643 2025-04-30
Safety and Efficacy Study of Immunotherapy With Rituximab and Interleukin-2 in Patients With Non-Hodgkin's Lymphoma
Thomas Jefferson University
Phase 2 Completed
Clinical Trials
8 trialsNCT01898793 2024-01-17
Cytokine-induced Memory-like NK Cells in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
Washington University School of Medicine
Phase 1/2 Terminated
NCT01856023 2023-12-05
PROCLIVITY02
Clinigen, Inc.
Phase 4 Terminated
NCT01883323 2019-11-08
Tumor-Infiltrating Lymphocytes And Low-Dose Interleukin-2 Therapy Following Cyclophosphamide And Fludarabine In Patients With Melanoma
University Health Network, Toronto
Phase 2 Completed
NCT00553306 2017-02-15
Laboratory-Treated T Cells and Aldesleukin After Cyclophosphamide in Treating Patients With Stage IV Melanoma
Fred Hutchinson Cancer Center
Phase 1/2 Completed
NCT00311467 2012-05-16
Combined Treatment With Capecitabine and Immunotherapy Versus Immunotherapy Alone in Advanced Renal Cell Carcinoma
Central European Cooperative Oncology Group
Phase 3 Terminated
NCT00089453 2012-04-19
Study of KIR-Ligand Mismatched Haplo-Identical Natural Killer Cells Transfused Before Autologous Stem Cell Transplant
University of Arkansas
Phase 1 Completed
NCT00283829 2007-11-29
Immunotherapy After Chemotherapy for Patients With Hormone Refractory Metastatic Prostate Cancer
University of Washington
Phase 1/2 Completed